Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 May-Jun;21(3):249-255.
doi: 10.1370/afm.2966.

Baseline Characteristics of PATHWEIGH: A Stepped-Wedge Cluster Randomized Study for Weight Management in Primary Care

Leigh Perreault  1   2 , Krithika Suresh  3   4 , Carlos Rodriguez  3 , L Miriam Dickinson  3 , Emileigh Willems  5 , Peter C Smith  3 , Johnny Williams Jr  3 , R Mark Gritz  4   6 , Jodi Summers Holtrop  3   4
Affiliations
Randomized Controlled Trial

Baseline Characteristics of PATHWEIGH: A Stepped-Wedge Cluster Randomized Study for Weight Management in Primary Care

Leigh Perreault et al. Ann Fam Med. 2023 May-Jun.

Abstract

Purpose: To describe the characteristics of patients and practice of clinicians during standard-of-care for weight management in a large, multiclinic health system before the implementation of PATHWEIGH, a pragmatic weight management intervention.

Methods: We analyzed baseline characteristics of patients, clinicians, and clinics during standard-of-care for weight management before the implementation of PATHWEIGH, which will be evaluated for effectiveness and implementation in primary care using an effectiveness-implementation hybrid type-1 cluster randomized stepped-wedge clinical trial design. A total of 57 primary care clinics were enrolled and randomized to 3 sequences. Patients included in the analysis met the eligibility requirements of age ≥18 years and body mass index (BMI) ≥25 kg/m2 and had a weight-prioritized visit (defined a priori) during the period March 17, 2020 to March 16, 2021.

Results: A total of 12% of patients aged ≥18 years and with a BMI ≥25 kg/m2 seen in the 57 practices during the baseline period (n = 20,383) had a weight-prioritized visit. The 3 randomization sequences of 20, 18, and 19 sites were similar, with an overall mean patient age of 52 (SD 16) years, 58% women, 76% non-Hispanic White patients, 64% with commercial insurance, and with a mean BMI of 37 (SD 7) kg/m2. Documented referral for anything weight related was low (<6%), and 334 prescriptions of an antiobesity drug were noted.

Conclusions: Of patients aged ≥18 years and with a BMI ≥25 kg/m2 in a large health system, 12% had a weight-prioritized visit during the baseline period. Despite most patients being commercially insured, referral to any weight-related service or prescription of antiobesity drug was uncommon. These results fortify the rationale for trying to improve weight management in primary care.

Trial registration: ClinicalTrials.gov NCT04678752.

Keywords: body mass index; primary care; weight management.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
CONSORT diagram. BMI = body mass index; CONSORT = Consolidated Standards of Reporting Trials.
See this image and copyright information in PMC

References

    1. Afshin A, Forouzanfar MH, Reitsma MB, et al. ; GBD 2015 Obesity Collaborators . Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017; 377(1): 13-27. 10.1056/NEJMoa1614362 - DOI - PMC - PubMed
    1. Swinburn BA, Sacks G, Hall KD, et al. . The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011; 378(9793): 804-814. 10.1016/S0140-6736(11)60813-1 - DOI - PubMed
    1. Kaplan LM, Golden A, Jinnett K, et al. . Perceptions of barriers to effective obesity care: results from the national ACTION study. Obesity (Silver Spring). 2018; 26(1): 61-69. 10.1002/oby.22054 - DOI - PubMed
    1. Bohula EA, Scirica BM, Inzucchi SE, et al. ; CAMELLIA-TIMI 61 Steering Committee Investigators . Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet. 2018; 392(10161): 2269-2279. 10.1016/S0140-6736(18)32328-6 - DOI - PubMed
    1. Bohula EA, Wiviott SD, McGuire DK, et al. ; CAMELLIA–TIMI 61 Steering Committee and Investigators . Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med. 2018; 379(12): 1107-1117. 10.1056/NEJMoa1808721 - DOI - PubMed

Publication types

Substances

Associated data